Abstract

To observe the efficacy of modified electroconvulsive therapy in conjunction with aripiprazole and lorazepam in patients with schizophrenia. The study population for our research comprised 100 patients with schizophrenia, who were admitted to our hospital during the period from June 2022 to June 2023. Two groups were formed; each consisting of 50 randomly assigned patients. For the control group, the treatment regimen included aripiprazole together with lorazepam, while the observation group received modified electroconvulsive therapy in addition to the control group’s treatment for 8 w. Assessment of the patient’s psychological symptoms was conducted utilizing the positive and negative syndrome scale, with their cognitive function assessed using the Wechsler adult intelligence scale. Observations and recordings of any adverse reactions that arose during the treatment were made for both groups. Prior to the initiation of treatment, statistical analysis revealed no significant differences (p>0.05) in positive and negative syndrome scale scores and Wechsler adult intelligence scale scores between the control group and the observation group. Subsequent to the treatment, both groups registered noteworthy declines in positive and negative syndrome scale scores compared to their pre-treatment scores, demonstrating statistical significance (p<0.05). Additionally, the observation group achieved lower scores than the control group, exhibiting a remarkable difference (p<0.05). As for Wechsler adult intelligence scale scores, both groups exhibited notable improvements after the treatment, with the observation group displaying a greater level of progress as opposed to the control group (p<0.05). No statistically significant distinction in the frequency of adverse reactions was observed between the two groups during the treatment duration (p>0.05). The incorporation of modified electroconvulsive therapy in conjunction with aripiprazole and lorazepam showcases notable efficacy in symptom improvement and cognitive function enhancement for individuals with schizophrenia, accompanied by a commendable safety profile.